Taysha Gene Therapies, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. Filed March 19, 2024. Taysha is a clinical-stage gene-therapy company with no approved products and no product-sales revenue.
Business context and pipeline
The company’s principal development focus is TSHA-102, an AAV9 gene therapy for Rett syndrome, being studied in Phase 1/2 adolescent/adult and pediatric trials. Most other research and development has been paused or deprioritized. In September 2023, Taysha discontinued its company-sponsored TSHA-120 program for giant axonal neuropathy (GAN) after FDA feedback on a potential registrational path; in January 2024, it initiated transfer of the IND and trial materials to NINDS and discussed returning rights to the originating advocacy organization.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $15.5 million | $2.5 million |
| Research and development expense | $56.8 million | $91.2 million |
| General and administrative expense | $30.0 million | $37.4 million |
| Operating loss | $72.4 million | $162.4 million |
| Net loss | $111.6 million | $166.0 million |
| Net cash used in operations | $73.0 million | $88.4 million |
Revenue came from the Astellas agreement, not product sales: $13.2 million for Rett research and development activities and $2.3 million upon expiration of the GAN option. Operating expenses were $87.9 million in 2023. A conventional product margin is not meaningful because the company has no product sales.
At year-end, cash and cash equivalents were $143.9 million; total assets were $172.7 million, total liabilities $97.8 million, and stockholders’ equity $74.9 million. Management estimated cash would fund operations into 2026, subject to assumptions; the financial-statement note also states funding is expected to cover at least 12 months from issuance. Operating cash use plus investing cash use totaled $80.4 million. Financing activities provided $136.4 million, largely from the August 2023 private placement.
In November 2023, Taysha borrowed $40.0 million from Trinity Capital, secured by substantially all assets. The stated annual rate is the greater of prime plus 4.50% or 12.75%; interest-only payments run initially for 36 months, potentially extendable to 48 months, with maturity November 2028. The loan includes covenants, prepayment premiums and a 5% end-of-term payment. The balance sheet reports term-loan fair value of $40.5 million. Lease payments under noncancelable leases totaled $31.8 million at year-end.
Material changes and unusual items
- Net loss narrowed by $54.4 million, principally as 2022 included a $36.4 million noncash impairment charge for the North Carolina manufacturing facility and R&D spending fell after pipeline reprioritization and workforce reductions. Rett trial costs partially offset the R&D decline.
- 2023 included a $34.7 million noncash warrant fair-value expense, a $1.4 million debt-extinguishment loss and a $1.5 million fair-value change in the Trinity loan. These items materially widened the gap between operating loss and net loss.
- The August 2023 private placement generated $150.0 million gross and $140.3 million net proceeds. Common shares outstanding increased from 63.2 million at year-end 2022 to 187.0 million at year-end 2023.
- The company recorded a $1.1 million noncash impairment charge in 2023, including impairment of equipment classified as held for sale. A $3.5 million Rett license milestone was triggered and paid in 2023.
Clinical outlook, commentary and risks
By the filing date, two adult Rett patients had been treated at the low dose. Taysha reported no treatment-emergent serious adverse events through week 35 for the first patient and week 19 for the second. Investigators and caregivers reported improvements across several measures; the observations are preliminary, based on very few patients, and from an open-label study. In February 2024, the IDMC cleared dose escalation in the adolescent/adult trial and dosing of a second pediatric patient. Management expected the first high-dose adult patient in Q2 2024, adult cohort 2 data in the second half of 2024, initial pediatric cohort 1 data in mid-2024 and cohort 2 data in the second half of 2024. These are forward-looking expectations, not guaranteed outcomes.
TSHA-102 has FDA orphan-drug, rare-pediatric-disease and Fast Track designations; the U.K. granted CTA clearance and ILAP designation in early 2024. Designations do not assure approval. Key risks include clinical efficacy and safety uncertainty, trial enrollment and regulatory delays, AAV manufacturing and third-party dependence, continued financing needs, dilution, and secured-debt obligations. Trofinetide was approved for Rett syndrome in 2023, and other gene-therapy programs are in development. A January 2024 shareholder derivative suit names the company as a nominal defendant and concerns the August 2023 private placement; damages are unspecified and the company recorded no liability because loss could not be reasonably estimated. The independent auditor issued an unmodified opinion on the financial statements; it did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether subsequent TSHA-102 trial updates support the preliminary observations, especially at higher doses and in additional patients, and whether safety findings change.
- Whether the 2024 dosing and data milestones were achieved, and any FDA or other regulator feedback on trial design and the path to approval.
- Cash burn, financing runway and any need for additional capital; also the dilution and fully diluted share count following the 2023 placement and subsequent equity awards.
- Trinity loan terms, collateral and covenants, including the effective interest rate, extension conditions, end-of-term fee and repayment capacity.
- Progress of the TSHA-120 transfer and any rights or partnership arrangements for deprioritized programs; status and potential cost of the derivative lawsuit.